These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21281966)

  • 1. Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy.
    Amrein L; Davidson D; Shawi M; Petruccelli LA; Miller WH; Aloyz R; Panasci L
    Leuk Res; 2011 Aug; 35(8):1080-6. PubMed ID: 21281966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib sensitizes CLL lymphocytes to chlorambucil.
    Aloyz R; Grzywacz K; Xu ZY; Loignon M; Alaoui-Jamali MA; Panasci L
    Leukemia; 2004 Mar; 18(3):409-14. PubMed ID: 14712290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase.
    Amrein L; Loignon M; Goulet AC; Dunn M; Jean-Claude B; Aloyz R; Panasci L
    J Pharmacol Exp Ther; 2007 Jun; 321(3):848-55. PubMed ID: 17351105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro.
    Amrein L; Rachid Z; Jean-Claude B; Soulières D; Aloyz R; Panasci L
    Leukemia; 2011 Sep; 25(9):1512-6. PubMed ID: 21647162
    [No Abstract]   [Full Text] [Related]  

  • 5. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards.
    Muller C; Christodoulopoulos G; Salles B; Panasci L
    Blood; 1998 Oct; 92(7):2213-9. PubMed ID: 9746757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia.
    Christodoulopoulos G; Malapetsa A; Schipper H; Golub E; Radding C; Panasci LC
    Clin Cancer Res; 1999 Aug; 5(8):2178-84. PubMed ID: 10473103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
    Hebb J; Assouline S; Rousseau C; Desjardins P; Caplan S; Egorin MJ; Amrein L; Aloyz R; Panasci L
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):643-51. PubMed ID: 21120481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
    Amrein L; Hernandez TA; Ferrario C; Johnston J; Gibson SB; Panasci L; Aloyz R
    Br J Haematol; 2008 Dec; 143(5):698-706. PubMed ID: 19062342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair.
    Panasci L; Paiement JP; Christodoulopoulos G; Belenkov A; Malapetsa A; Aloyz R
    Clin Cancer Res; 2001 Mar; 7(3):454-61. PubMed ID: 11297233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate.
    Chou CJ; O'Hare T; Lefebvre S; Alvarez D; Tyner JW; Eide CA; Druker BJ; Gottesfeld JM
    PLoS One; 2008; 3(10):e3593. PubMed ID: 18974832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin.
    Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L
    Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
    Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ
    Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells.
    Allen JC; Talab F; Zuzel M; Lin K; Slupsky JR
    Blood; 2011 Feb; 117(8):2414-22. PubMed ID: 21220745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
    Secchiero P; Voltan R; di Iasio MG; Melloni E; Tiribelli M; Zauli G
    Clin Cancer Res; 2010 Mar; 16(6):1824-33. PubMed ID: 20215548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
    Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
    Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evidence for homologous recombinational repair in resistance to melphalan.
    Wang ZM; Chen ZP; Xu ZY; Christodoulopoulos G; Bello V; Mohr G; Aloyz R; Panasci LC
    J Natl Cancer Inst; 2001 Oct; 93(19):1473-8. PubMed ID: 11584063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
    Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.